A phase I/II study of numonafide for the treatment of refractory acute myelogenous leukemia (AML)

Trial Profile

A phase I/II study of numonafide for the treatment of refractory acute myelogenous leukemia (AML)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2015

At a glance

  • Drugs Numonafide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2015 New trial record
    • 01 Apr 2015 Panther Biotechnology plans to file an IND application in the 4th quarter of 2015 and intends to initiate this study by the end of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top